Cepheid's Q1 Revenue Jumps 27 Percent; Clinical Market Becoming 'Key Driver' | GenomeWeb
NEW YORK (GenomeWeb News) — Cepheid today said first-quarter revenues increased 27 percent as R&D spending rose 19 percent and profit declined around 6 percent.
 
Total receipts for the three months ended March 31 increased to $25.5 million from $20.1 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.